Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
This randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulat...
Full description
Bibliographic Details
| Main Authors: |
Parissis, J,
Adamopoulos, S,
Antoniades, C,
Kostakis, G,
Rigas, A,
Kyrzopoulos, S,
Iliodromitis, E,
Kremastinos, D |
|---|
| Format: | Journal article
|
|---|
| Language: | English |
|---|
| Published: |
2004
|
|---|